Sign-up for our newsletter
Protocols & Methods
Reagents & Resources
IMPC / KOMP Data
Not signed up.
Islet Autoantibodies in T2DM Patients with Gastroparesis
While gastroparesis in type 1 diabetes mellitus (T1DM) patients is well recognized as a long term complication of diabetes mellitus, gastroparesis is being increasingly diagnosed in type 2 diabetes (T2DM). Our overall hypothesis is that T2DM who develop gastroparesis are more likely to have an autoimmune form of the disease, i.e. latent autoimmune diabetes in adults (LADA), more closely related to T1DM than those who do not. This will be investigated through the following three specific aims. Aim 1. 1a) Determine the prevalence of islet autoantibodies (anti-glutamic acid decarboxylase-65 [GAD65] antibody, anti-islet cell antibody, anti-insulin antibody) in T2DM patients with gastroparesis. 1b) Compare the prevalence of islet autoantibodies in symptomatic T2DM patients with and without delayed gastric emptying. Aim 2. 2a) Determine the gastroparesis phenotypic profile (gastric emptying times and gastroparesis symptoms as determined by the Gastroparesis Cardinal Symptoms Index [GCSI]) of T2DM gastroparesis patients having islet autoantibodies. 2b) Compare the gastroparesis symptoms and rate of gastric emptying of T2DM gastroparesis patients with islet autoantibodies to T2DM gastroparesis patients without islet autoantibodies and to T1DM with gastroparesis. Aim 3. 3a) Determine the diabetic phenotypic profile (body weight, insulin sensitivity measured by HOMA-IR, C peptide level, and glucose control measured by fasting glucose, fructosamine level, and A1c) of T2DM gastroparesis patients having islet autoantibodies. 3b) Compare the diabetic phenotypic profile of T2DM gastroparesis patients with islet autoantibodies to patients with T2DM gastroparesis patients without islet autoantibodies and to T1DM with gastroparesis. Through these studies on islet autoantibodies in diabetic patients with gastroparesis, we hope to gain insight in the phenotypic characteristics of this complication of diabetes - diabetic gastroparesis. Identification of patients with T2DM with gastroparesis who have islet autoantibodies, representing LADA, may also have importance in their disease management. It has been suggested that LADA patients should be treated with insulin earlier, or perhaps with immune modulation, as this is thought to preserve beta cell function and improve outcomes.
Drag a column header and drop it here to group by that column
Islet Autoantibodies in T2DM Patients with Gastroparesis (Parkman, Henry)
View Progress Report Document
No uploaded documents found.
Year: 2015; Items: 2
Diabetes-related autoantibodies in diabetic gastroparesis.
Singla R, Homko C, Schey R, Parkman HP
Digestive diseases and sciences
, 2015 (60), 1733 - 1737
Outcomes and Factors Associated With Reduced Symptoms in Patients with Gastroparesis.
Pasricha PJ, Yates KP, Nguyen L, Clarke J, Abell TL, Farrugia G, Hasler WL, Koch KL, Snape WJ, McCallum RW, Sarosiek I, Tonascia J, Miriel LA, Lee L, Hamilton F, Parkman HP
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Gastro-Intestinal (GI) Committee has the principal function of furthering the mission of the consortium with regard to diabetic gastro-intestinal (GI) and liver disease
Curation Flag Information
New comment to be added:
No records to display.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!